Infusion of ADR-001 (Mesenchymal stem cell) ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 66 | IgA nephropathy | 1 |
66. IgA nephropathy
Clinical trials : 255 / Drugs : 255 - (DrugBank : 79) / Drug target genes : 35 - Drug target pathways : 137
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04342325 (ClinicalTrials.gov) | June 15, 2020 | 8/4/2020 | The Clinical Trial of ADR-001 for IgA Nephropathy | Open-label, Multiple-center, Dose-Escalation Study to Evaluate the Safety and Tolerability of ADR-001 for the Treatment for Immunoglobulin A (IgA) Nephropathy | Glomerulonephritis , IGA | Biological: infusion of ADR-001 (Mesenchymal stem cell) | Nagoya University | Rohto Pharmaceutical Co., Ltd. | Active, not recruiting | 20 Years | N/A | All | 9 | Phase 1 | Japan |